| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 488 | FAB1062G | |||
| Allophycocyanin | FAB1062A | |||
| Biotin | BAF1062 | |||
| Phycoerythrin | FAB1062P | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB1062P | |||
| Carrier Free | FAB1062A | |||
| Carrier Free | FAB1062G | |||
| Carrier Free | AF1062-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB1835-SP | |||
| Carrier Free | MAB1835-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1494-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-493-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB293-SP | |||
| Carrier Free | MAB293-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-664SS | |||
| Azide and BSA Free | NBP2-81007 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-293-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-16897-20ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB397-SP | |||
| Carrier Free | MAB397-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1042-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-259-SP | |||
![Immunohistochemistry: VEGF Antibody (VG1) - BSA Free [NB100-664] - HPG induces less VEGF production, less myofibroblast differentiation and lower macrophage activation. The expression of VEGF, alpha-SMA and MAC387 in the peritoneal tissue sections was examined using a routine immunohistochemical method. Data were a typical microscopic view of the peritoneal tissue sections in each group. a VEGF was detected using mouse monoclonal anti-VEGF antibody from Novus. Left graph a typical microscopic view, Dark brown stain VEGF-expressing cells (pointed by red arrows), Bv blood vessels, M muscle, black small bar 10 um. Right graph VEGF-expressing cells per 200 um PM length in cross sections. Data were presented as mean +/- SD (n = 6) and were analyzed using t test. Image collected and cropped by CiteAb from the following publication (//translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-1098-z) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG1-BSA-Free-Immunohistochemistry-NB100-664-img0015.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib transcriptionally inhibited VEGF-A expression through decreasing binding of STAT3 on promoter of VEGF-A.(A) Top, MDA-MB-231 cells co-transfected w/ a Renilla control vector & plasmids containing firefly luciferase gene driven by wild-type or STAT3 binding site-mutated VEGF-A promoter. After transfection for 48 h, cells treated w/ regorafenib for 24 h. Promoter activity analyzed by luciferase assay after regorafenib treatment. Bottom, MDA-MB-231 cells transfected w/ vector-control or STAT3-overexpression plasmid for 48 h. After , cells further co-transfected w/ Renilla & wild-type VEGF-A promoter & detect promoter activity as mentioned above. *p < 0.05, **p < 0.01. (B) After regorafenib treatment for 24 h, STAT3 binding site fragment detected by PCR in ChIP samples precipitated w/ STAT3 & rabbit IgG control antibodies in MDA-MB-231 cells. (C,D), MDA-MB-231 cells transfected, respectively, w/ control vector or VEGF-A overexpression plasmid (C) or STAT3 overexpression plasmid (D) for 48 h. After transfection, cells treated w/wo regorafenib for 24 h & subjected to WB assay or seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. (E) Cells treated w/ regorafenib at indicated dosages for 24 h & cell lysates analyzed by SHP-1 phosphatase activity assay. *p < 0.05, **p < 0.01. (F) MDA-MB-231 cells pretreated w/ pan-phosphatase inhibitor (left), or specific SHP-1 inhibitor (Middle) for 1 h before regorafenib treatment. Right, MDA-MB-231 cells transfected, respectively, w/ control siRNA or SHP-1 siRNA for 48 h. After transfection, cells treated w/wo regorafenib (10 μM) for 24 h. The protein levels analyzed by WB assay or cells seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-31020241682159.jpg)
![CXCR4 and CXCL12 expression in DLBCL. (a) Expression analysis of CXCR4 and CXCL12 in non-neoplastic control germinal center B cells (GC-B) and diffuse large B cell lymphoma cells (DLBCL) consisting of DLBCL-NGCB and DLCBL-GCB, by RQ-PCR. GCB-DLBCL were further subdivided into primary (DLBCL-pGCB) and transformed DLBCL (DLBCL-pGCB) originating from follicular lymphoma. (b) Expression analysis of CXCR4 and CXCL12 in DLBCL samples with early (stage 1) and advanced stage (stage 2–4) (left graphs) and DLBCL samples with and without bone marrow infiltration (right graphs) by RQ-PCR. (c) Probability of 5-year-survival in DLBCL patients (our cohort left panel and the cohort of Lenz et al. right [20]) stratified by the third quartile of CXCR4 expression, respectively. (d) Representative immunohistochemical stains of CXCR4 (I–III) and CXCL12 (IV–VI) on DLBCL samples (magnification 20×). mRNA expression levels were calculated as a relative expression in comparison to the GC-B cells. All images were captured using an Olympus BX51 microscope and an Olympus E-330 camera. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31554271), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab350_human-mouse-cxcl12-sdf-1-mab-clone-79018-41202410331984.jpg)
![Western Blot: TrkA/B [p Tyr707, p Tyr675, p Tyr706, p Tyr674] Antibody [NBP3-16897] - Western blot analysis of extracts of HeLa cells, using TrkA/B antibody (NBP3-16897) at 1:500 dilution.HeLa cells were treated by Pervanadate (1 nM) at 37C for 30 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 30s.](http://images.novusbio.com/fullsize/TrkA-B-[p-Tyr707-p-Tyr675-p-Tyr706-p-Tyr674]-Antibody-Western-Blot-NBP3-16897-img0001.jpg "Western Blot: TrkA/B [p Tyr707, p Tyr675, p Tyr706, p Tyr674] Antibody [NBP3-16897] - Western blot analysis of extracts of HeLa cells, using TrkA/B antibody (NBP3-16897) at 1:500 dilution.HeLa cells were treated by Pervanadate (1 nM) at 37C for 30 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 30s.")
